Xenix Medical wins FDA 510(k) clearance for Riva Anchor spinopelvic fixation system

# What happened Xenix Medical received FDA 510(k) clearance for its Riva Anchor Spinopelvic Fixation System. The device is intended to facilitate fusion of the sacroiliac (SI) joint when placed at the distal end of a posterior lumbar or thoracolumbar fusion construct. The company plans a limited commercial launch and is seeking clinicians interested in early adoption.

# Why this matters Fusion of the SI joint at the base of long posterior constructs affects the biomechanical stability of the entire construct. Xenix positions the Riva Anchor to address inconsistent fusion seen with other systems by combining mechanical fixation with a surface engineered to promote bone formation.

# What's in the system Pedicle Fixation System. Notable design elements:

• NanoACTIV surface technology: a proprietary combination of micro‑ and nano‑scale surface textures cleared under an FDA nanotechnology designation and described as eliciting osteogenic differentiation and an endogenous cellular and biochemical response.
• Self‑harvesting bone apertures intended to support postoperative bone growth and fusion.
• Compatibility with 5.5 mm and 6.0 mm rods and a dual‑lead fully threaded implant.
• Implantation intended for use with navigation, fluoroscopy, or an open approach.

# How the company positions the device Xenix emphasizes that NanoACTIV provides an osteogenic effect beyond pure stabilization. Company leadership says that while some competing devices focus on stabilization, the Riva Anchor aims to create an environment for arthrodesis at the SI joint, which the company describes as the biomechanical foundation of long fusion constructs.

A quoted neurosurgeon highlighted clinical concerns such as inconsistent fusion and hardware haloing or loosening with existing systems, and described Riva Anchor's surface designation as a differentiator for promoting fusion.

# Regulatory and clinical context The FDA cleared the device through the 510(k) pathway. NanoACTIV's FDA nanotechnology designation indicates the agency reviewed the device's nanoscale surface characteristics. The clearance covers the Riva Anchor intended for use with Xenix's posterior fixation system and standard intraoperative imaging guidance or open techniques.

# Commercial outlook and next steps Xenix is preparing a limited commercial launch and has provided a contact for clinicians to request participation or more information. The announcement does not include clinical outcome data or timelines for wider availability.

# Practical considerations for surgeons and hospitals